Is SoFi Stock a Buy Under $20?
After briefly flirting with penny‑stock territory during the 2022 bear…
Buy
76
HTEC Quote, Financials, Valuation and Earnings
Last price:
$28.26
Seasonality move
:
-1.64%
Day range:
$28.20 - $28.49
52-week range:
$23.77 - $31.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
5.7K
Avg. volume:
6.1K
1-year change:
4.15%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
$28.40 | -- | -- | -- | $0.00 | 0% | -- |
|
AGNG
Global X Aging Population ETF
|
$32.16 | -- | -- | -- | $0.14 | 0.9% | -- |
|
CANC
Tema Oncology ETF
|
$25.09 | -- | -- | -- | $0.73 | 1.99% | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
$21.11 | -- | -- | -- | $0.03 | 1.04% | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
$20.45 | -- | -- | -- | $0.15 | 1.29% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | 1.305 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 0.597 | -- | -- |
|
CANC
Tema Oncology ETF
|
-- | 0.860 | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | 0.658 | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | 0.803 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
ROBO Global Healthcare Technology & Innovation ETF vs. Competitors
-
Which has Higher Returns HTEC or AGNG?
Global X Aging Population ETF has a net margin of -- compared to ROBO Global Healthcare Technology & Innovation ETF's net margin of --. ROBO Global Healthcare Technology & Innovation ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About HTEC or AGNG?
ROBO Global Healthcare Technology & Innovation ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ROBO Global Healthcare Technology & Innovation ETF has higher upside potential than Global X Aging Population ETF, analysts believe ROBO Global Healthcare Technology & Innovation ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is HTEC or AGNG More Risky?
ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.146, which suggesting that the stock is 14.598% more volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.736, suggesting its less volatile than the S&P 500 by 26.366%.
-
Which is a Better Dividend Stock HTEC or AGNG?
ROBO Global Healthcare Technology & Innovation ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Global X Aging Population ETF offers a yield of 0.9% to investors and pays a quarterly dividend of $0.14 per share. ROBO Global Healthcare Technology & Innovation ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HTEC or AGNG?
ROBO Global Healthcare Technology & Innovation ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. ROBO Global Healthcare Technology & Innovation ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, ROBO Global Healthcare Technology & Innovation ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ROBO Global Healthcare Technology & Innovation ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns HTEC or CANC?
Tema Oncology ETF has a net margin of -- compared to ROBO Global Healthcare Technology & Innovation ETF's net margin of --. ROBO Global Healthcare Technology & Innovation ETF's return on equity of -- beat Tema Oncology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- CANCTema Oncology ETF-- -- -- -
What do Analysts Say About HTEC or CANC?
ROBO Global Healthcare Technology & Innovation ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Tema Oncology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ROBO Global Healthcare Technology & Innovation ETF has higher upside potential than Tema Oncology ETF, analysts believe ROBO Global Healthcare Technology & Innovation ETF is more attractive than Tema Oncology ETF.
Company Buy Ratings Hold Ratings Sell Ratings HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 CANCTema Oncology ETF0 0 0 -
Is HTEC or CANC More Risky?
ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.146, which suggesting that the stock is 14.598% more volatile than S&P 500. In comparison Tema Oncology ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HTEC or CANC?
ROBO Global Healthcare Technology & Innovation ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tema Oncology ETF offers a yield of 1.99% to investors and pays a quarterly dividend of $0.73 per share. ROBO Global Healthcare Technology & Innovation ETF pays -- of its earnings as a dividend. Tema Oncology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HTEC or CANC?
ROBO Global Healthcare Technology & Innovation ETF quarterly revenues are --, which are smaller than Tema Oncology ETF quarterly revenues of --. ROBO Global Healthcare Technology & Innovation ETF's net income of -- is lower than Tema Oncology ETF's net income of --. Notably, ROBO Global Healthcare Technology & Innovation ETF's price-to-earnings ratio is -- while Tema Oncology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ROBO Global Healthcare Technology & Innovation ETF is -- versus -- for Tema Oncology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -- CANCTema Oncology ETF-- -- -- --
-
Which has Higher Returns HTEC or IBBQ?
Invesco Nasdaq Biotechnology ETF has a net margin of -- compared to ROBO Global Healthcare Technology & Innovation ETF's net margin of --. ROBO Global Healthcare Technology & Innovation ETF's return on equity of -- beat Invesco Nasdaq Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- IBBQInvesco Nasdaq Biotechnology ETF-- -- -- -
What do Analysts Say About HTEC or IBBQ?
ROBO Global Healthcare Technology & Innovation ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Nasdaq Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ROBO Global Healthcare Technology & Innovation ETF has higher upside potential than Invesco Nasdaq Biotechnology ETF, analysts believe ROBO Global Healthcare Technology & Innovation ETF is more attractive than Invesco Nasdaq Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 IBBQInvesco Nasdaq Biotechnology ETF0 0 0 -
Is HTEC or IBBQ More Risky?
ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.146, which suggesting that the stock is 14.598% more volatile than S&P 500. In comparison Invesco Nasdaq Biotechnology ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HTEC or IBBQ?
ROBO Global Healthcare Technology & Innovation ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invesco Nasdaq Biotechnology ETF offers a yield of 1.04% to investors and pays a quarterly dividend of $0.03 per share. ROBO Global Healthcare Technology & Innovation ETF pays -- of its earnings as a dividend. Invesco Nasdaq Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HTEC or IBBQ?
ROBO Global Healthcare Technology & Innovation ETF quarterly revenues are --, which are smaller than Invesco Nasdaq Biotechnology ETF quarterly revenues of --. ROBO Global Healthcare Technology & Innovation ETF's net income of -- is lower than Invesco Nasdaq Biotechnology ETF's net income of --. Notably, ROBO Global Healthcare Technology & Innovation ETF's price-to-earnings ratio is -- while Invesco Nasdaq Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ROBO Global Healthcare Technology & Innovation ETF is -- versus -- for Invesco Nasdaq Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -- IBBQInvesco Nasdaq Biotechnology ETF-- -- -- --
-
Which has Higher Returns HTEC or IDNA?
iShares Genomics Immunology and Healthcare ETF has a net margin of -- compared to ROBO Global Healthcare Technology & Innovation ETF's net margin of --. ROBO Global Healthcare Technology & Innovation ETF's return on equity of -- beat iShares Genomics Immunology and Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -
What do Analysts Say About HTEC or IDNA?
ROBO Global Healthcare Technology & Innovation ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Genomics Immunology and Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ROBO Global Healthcare Technology & Innovation ETF has higher upside potential than iShares Genomics Immunology and Healthcare ETF, analysts believe ROBO Global Healthcare Technology & Innovation ETF is more attractive than iShares Genomics Immunology and Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 -
Is HTEC or IDNA More Risky?
ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.146, which suggesting that the stock is 14.598% more volatile than S&P 500. In comparison iShares Genomics Immunology and Healthcare ETF has a beta of 1.055, suggesting its more volatile than the S&P 500 by 5.473%.
-
Which is a Better Dividend Stock HTEC or IDNA?
ROBO Global Healthcare Technology & Innovation ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iShares Genomics Immunology and Healthcare ETF offers a yield of 1.29% to investors and pays a quarterly dividend of $0.15 per share. ROBO Global Healthcare Technology & Innovation ETF pays -- of its earnings as a dividend. iShares Genomics Immunology and Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HTEC or IDNA?
ROBO Global Healthcare Technology & Innovation ETF quarterly revenues are --, which are smaller than iShares Genomics Immunology and Healthcare ETF quarterly revenues of --. ROBO Global Healthcare Technology & Innovation ETF's net income of -- is lower than iShares Genomics Immunology and Healthcare ETF's net income of --. Notably, ROBO Global Healthcare Technology & Innovation ETF's price-to-earnings ratio is -- while iShares Genomics Immunology and Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ROBO Global Healthcare Technology & Innovation ETF is -- versus -- for iShares Genomics Immunology and Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -- IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Apple Stock Not Joining the Broader Market Rally?
The S&P 500 has sprinted 4.92% higher so far in…
Will Google Stock Double by 2030?
If you bought Alphabet (NASDAQ: GOOGL) when Gmail launched in…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 54x
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 42x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
49
NKE alert for Jun 28
Nike [NKE] is up 15.29% over the past day.
Buy
81
KTOS alert for Jun 28
Kratos Defense & Security Solutions [KTOS] is up 10.89% over the past day.
Sell
44
GDXU alert for Jun 28
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 10.89% over the past day.
